Acute Kidney Injury in Lymphoma: A Single Centre Experience

Khalil, Muhammad Abdul Mabood; Latif, Hira; Rehman, Abdur; Kashif, Waqar; Awan, Safia; Khalil, Zarghona; Mushtaq, Uziar; Ahmad, Maria; Khalil, Muhammad; Sami, Manickam Ranga; Tan, Jackson

doi:10.1155/2014/272961

Cited by 21 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, about one‐third of the patients with cancer experienced an AKI event at least once. As reported in previous studies, hematologic malignancy was the most common type of cancer associated with AKI development (55.4%), which was a similar incidence in our study …”

Section: Discussionsupporting

confidence: 91%

Acute kidney injury predicts all‐cause mortality in patients with cancer

Kang

Park

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Background Acute kidney injury (AKI) is a critical issue in cancer patients because it is not only a morbid complication but also able to interrupt timely diagnostic evaluation or planned optimal treatment. However, the impact of AKI on overall mortality in cancer patients remains unclear. Methods We conducted a retrospective cohort study of 67 986 cancer patients, from 2004 to 2013 to evaluate the relationship between AKI and all‐cause mortality. We used KDIGO AKI definition and grading system. Results During 3.9 ± 3.1 years of follow‐up, 33.8% of the patients experienced AKI at least once. Among AKI events, stage 1, 2, and 3 was 71.0%, 13.8%, and 15.1%, respectively. AKI incidence was highest in hematologic malignancies, followed by urinary tract cancer, and hepatocellular carcinoma. Male sex, older age, underlying diabetes and hypertension, lower serum albumin and plasma hemoglobin, more frequent radio‐contrast exposure, entrance of clinical trials, and receiving chemotherapy were associated with AKI occurrence. AKI development was an independent risk factor for elevated mortality in cancer patients with dose‐responsive manner (Stage 1, hazard ratio [HR] 1.183, 95% confidence interval [CI] 1.145‐1.221, P < 0.001; Stage 2, HR 1.710, 95% CI 1.629‐1.796; Stage 3, HR 2.000, 95% CI 1.910‐2.095; No AKI, reference group) even after adjustment. This tendency was reproduced in various cancer types except thyroid cancer and in various treatment modalities, however, not shown in patients with baseline renal dysfunction. Conclusion AKI was an independent risk factor for all‐cause mortality in overall cancer patients with dose‐responsive manner.

show abstract

Section: Discussionsupporting

confidence: 91%

Acute kidney injury predicts all‐cause mortality in patients with cancer

Kang

Park

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Acute kidney failure occurs in 12% to 36% of patients with cancer and is accompanied by substantial morbidity and mortality . From 16% to 23% of patients with cancer who are admitted to the ICU develop severe renal failure and require renal replacement therapy .…”

Section: Icu Referral Of Critically Ill Patients With Cancermentioning

confidence: 99%

“…75 Acute kidney failure occurs in 12% to 36% of patients with cancer and is accompanied by substantial morbidity and mortality. [76][77][78] From 16% to 23% of patients with cancer who are admitted to the ICU develop severe renal failure and require renal replacement therapy. 79,80 The etiology of renal failure in patients with cancer is often multifactorial and can be caused by the tumor itself or by drug-related toxicity.…”

Section: Indications For Icu Admission Of Patients With Cancermentioning

confidence: 99%

Critical care of patients with cancer

Shimabukuro‐Vornhagen

Böll

Kochanek

et al. 2016

CA A Cancer J Clinicians

111

View full text Add to dashboard Cite

Answer questions and earn CME/CNE The increasing prevalence of patients living with cancer in conjunction with the rapid progress in cancer therapy will lead to a growing number of patients with cancer who will require intensive care treatment. Fortunately, the development of more effective oncologic therapies, advances in critical care, and improvements in patient selection have led to an increased survival of critically ill patients with cancer. As a consequence, critical care has become an important cornerstone in the continuum of modern cancer care. Although, in many aspects, critical care for patients with cancer does not differ from intensive care for other seriously ill patients, there are several challenging issues that are unique to this patient population and require special knowledge and skills. The optimal management of critically ill patients with cancer necessitates expertise in oncology, critical care, and palliative medicine. Cancer specialists therefore have to be familiar with key principles of intensive care for critically ill patients with cancer. This review provides an overview of the state-of-the-art in the individualized management of critically ill patients with cancer. CA Cancer J Clin 2016. © 2016 American Cancer Society.

show abstract

“…In this nationally representative sample of hospitalizations with TLS, we demonstrate higher mortality, adverse discharge and longer LOS in persons with AKI‐D. Previous analyses studying AKI in TLS have either been single‐center studies, have not captured the national epidemiology or have not delineated the impact of dialysis requirement in AKI . International studies have demonstrated that AKI and dialysis requirement are strong predictors of worse outcome in TLS .…”

Section: Discussionmentioning

confidence: 73%

“…Previous analyses studying AKI in TLS have either been single-center studies, have not captured the national epidemiology or have not delineated the impact of dialysis requirement in AKI. 3,7 International studies have demonstrated that AKI and dialysis requirement are strong predictors of worse outcome in TLS. 8 However, to the best of our knowledge, this is the first study demonstrating the frequency, associations and impact of AKI-D in the United States with nationally-representative estimates.…”

Section: Discussionmentioning

confidence: 99%

Impact of dialysis requirement on outcomes in tumor lysis syndrome

et al. 2016

View full text Add to dashboard Cite

Tumor lysis syndrome (TLS) is a life threatening emergency due to destruction and massive release of intracellular metabolites from cancer cells often resulting in acute kidney injury (AKI), sometimes severe enough to require dialysis (AKI-D). The impact of dialysis requirement in AKI has not been explored. We utilized data from the Nationwide Inpatient Sample and using International Classification of Diseases, 9th Revision, diagnoses codes for TLS, AKI and dialysis, evaluated the incidence, risk factors and impact of AKI-D on mortality, adverse discharge and length of stay (LOS). Survey multivariable logistic regression was used to compute adjusted Odds Ratios (aOR and 95% confidence intervals (CI). An estimated 12% (2,919) of all TLS hospitalizations (n = 22 875) develop AK-D. After adjustment for confounders, AKI-D was associated with greater odds of mortality (aOR 1.98; (95% CI 1.60-2.45)), adverse discharge (aOR 1.63 (95% CI 1.19-2.24)) and longer LOS (19 vs 14.6 days; P < 0.01) compared with those without AKI-D. Further studies to evaluate the association of AKI-D on long-term outcomes in patients with TLS are needed.

show abstract

Acute Kidney Injury in Lymphoma: A Single Centre Experience

Cited by 21 publications

References 25 publications

Acute kidney injury predicts all‐cause mortality in patients with cancer

Acute kidney injury predicts all‐cause mortality in patients with cancer

Critical care of patients with cancer

Impact of dialysis requirement on outcomes in tumor lysis syndrome

Contact Info

Product

Resources

About